/ Source: MarketWire
For further information, please contact: Dan Suesskind, Teva Pharmaceutical Industries Ltd. 972-2-941-1717 Chief Financial Officer George Barrett, Corp. E. V.P. - Global Teva Pharmaceutical Industries Ltd. (215) 591-3030 pharmaceutical Markets Chief Executive Officer Teva North America Liraz Kalif / Teva Pharmaceutical Industries Ltd. 972-3-926-7281 Kevin Mannix, Teva North America (215) 591-8912 Investor Relations Sven Andréasson Active Biotech +46 46 19 20 49 President & CEO Tomas Leanderson Active Biotech +46 46 19 20 95 Chief Scientific Officer Cecilia Hofvander Active Biotech +46 46 19 11 22 Manager Corporate Communication
INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY -- http://hugin.info/1002/R/1166589/228490.pdf
Copyright © Hugin ASA 2007. All rights reserved.